UK markets close in 7 hours 26 minutes
  • FTSE 100

    6,891.42
    +0.93 (+0.01%)
     
  • FTSE 250

    22,249.73
    -18.73 (-0.08%)
     
  • AIM

    1,245.41
    -0.20 (-0.02%)
     
  • GBP/EUR

    1.1529
    +0.0027 (+0.23%)
     
  • GBP/USD

    1.3789
    +0.0037 (+0.27%)
     
  • BTC-GBP

    46,823.27
    +2,455.27 (+5.53%)
     
  • CMC Crypto 200

    1,395.45
    +101.46 (+7.84%)
     
  • S&P 500

    4,141.59
    +13.60 (+0.33%)
     
  • DOW

    33,677.27
    -68.13 (-0.20%)
     
  • CRUDE OIL

    60.92
    +0.74 (+1.23%)
     
  • GOLD FUTURES

    1,745.30
    -2.30 (-0.13%)
     
  • NIKKEI 225

    29,620.99
    +82.29 (+0.28%)
     
  • HANG SENG

    28,869.31
    +372.06 (+1.31%)
     
  • DAX

    15,226.52
    -7.84 (-0.05%)
     
  • CAC 40

    6,198.56
    +14.46 (+0.23%)
     

Primary Biliary Cholangitis Epidemiology Forecast Report 2017-2020 & 2021-2030 - ResearchAndMarkets.com

·4-min read

The "Primary Biliary Cholangitis - Epidemiology Forecast 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Primary biliary cholangitis (PBC) - Epidemiology Forecast - 2030' report delivers an in-depth understanding of the Primary biliary cholangitis, historical and forecasted epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Primary biliary cholangitis Epidemiology

The Primary biliary cholangitis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The total prevalent cases of PBC patients are increasing in 7MM during the study period, i.e. 2017-2030.

The disease epidemiology covered in the report provides historical as well as forecasted PBC symptoms epidemiology segmented as the Total Diagnosed Prevalent cases of Primary biliary cholangitis, Gender-specific cases of Primary biliary cholangitis, and Age-specific cases of Primary biliary cholangitis. The report includes the prevalent scenario of Primary biliary cholangitis symptoms in 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise - Primary biliary cholangitis Epidemiology

The epidemiology segment also provides the Primary biliary cholangitis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total diagnosed prevalent cases of Primary biliary cholangitis associated in 7MM countries were 253,146 in 2020.

  • As per the estimates, the United States has the largest prevalent population of PBC.

  • Among the EU5 countries, Germany had the highest prevalent cases of PBC, followed by France. On the other hand, France had the lowest prevalent cases with 11,835 cases in 2020.

Report Highlights

  • 11-year Forecast of Primary biliary cholangitis epidemiology

  • 7MM Coverage

  • Total Diagnosed Prevalent Cases of Primary biliary cholangitis

  • Prevalent Cases according to segmentation: Gender-specific cases of Primary biliary cholangitis

  • Prevalent Cases according to segmentation: Age-specific cases of Primary biliary cholangitis

KOL Views

We interview KOLs, and SME's opinion through primary research to fill the data gaps and validate the secondary research. the opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM for the patient population about Primary biliary cholangitis?

  • What are the key findings of the Primary biliary cholangitis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?

  • What would be the total number of patients of Primary biliary cholangitis across the 7MM during the forecast period (2017-2030)?

  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?

  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?

  • What are the disease risk, burden, and unmet needs of the Primary biliary cholangitis?

  • What are the currently available treatments for Primary biliary cholangitis?

Key Assessments

  • Patient Segmentation

  • Disease Risk and Burden

  • Risk of disease by the segmentation

  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States

  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)

  • Japan

Key Topics Covered:

1 Key Insights

2 Executive Summary

3 Organizations

4 Epidemiology and Market Methodology

5 Primary Biliary Cholangitis (PBC): Market Overview at a Glance

5.1 Total Market Share (%) Distribution of Primary Biliary Cholangitis (PBC) in 2017

5.2 Total Market Share (%) Distribution of Primary Biliary Cholangitis (PBC) in 2030

6 Primary Biliary Cholangitis (PBC): Market Overview at a Glance

6.1 introduction

6.2 Pathophysiology

6.3 Genetics, Epigenetics, and Environmental Factors in PBC Pathogenesis

6.4 Symptoms

6.5 Histology

6.6 Clinical Features

6.7 Diagnosis

6.7.1 Diagnostic Guidelines

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Total Cases of Primary Biliary Cholangitis (PBC) in 7MM

7.4 United States

7.4.1 Diagnosed Prevalent Cases of Primary Biliary Cholangitis (PBC) in the United States

7.4.2 Gender-specific Cases of Primary Biliary Cholangitis (PBC) in the United States

7.4.3 Age-specific Cases of Primary Biliary Cholangitis (PBC) in the United States

7.5 EU5 Countries

7.6 Germany

7.7 France

7.8 Italy

7.9 Spain

7.10 UK

7.11 Japan

8 KOL Views

9 Bibliography

10 Appendix

For more information about this report visit https://www.researchandmarkets.com/r/q5crdm

View source version on businesswire.com: https://www.businesswire.com/news/home/20210302005551/en/

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900